Publications
Detailed Information
A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ji Young | - |
dc.contributor.author | Cho, Tae-Min | - |
dc.contributor.author | Park, Jung Min | - |
dc.contributor.author | Park, Soeun | - |
dc.contributor.author | Park, Minsu | - |
dc.contributor.author | Dal Nam, Kee | - |
dc.contributor.author | Ko, Dongmi | - |
dc.contributor.author | Seo, Juyeon | - |
dc.contributor.author | Kim, Seongjae | - |
dc.contributor.author | Jung, Eunsun | - |
dc.contributor.author | Farrand, Lee | - |
dc.contributor.author | Nguyen, Cong-Truong | - |
dc.contributor.author | Hoang, Van-Hai | - |
dc.contributor.author | La, Minh Thanh | - |
dc.contributor.author | Ann, Jihyae | - |
dc.contributor.author | Nam, Gibeom | - |
dc.contributor.author | Park, Hyun-Ju | - |
dc.contributor.author | Lee, Jeewoo | - |
dc.contributor.author | Kim, Yoon-Jae | - |
dc.contributor.author | Seo, Jae Hong | - |
dc.date.accessioned | 2022-09-30T05:51:34Z | - |
dc.date.available | 2022-09-30T05:51:34Z | - |
dc.date.created | 2022-06-16 | - |
dc.date.issued | 2022-06 | - |
dc.identifier.citation | Oncogene, Vol.41 No.23, pp.3289-3297 | - |
dc.identifier.issn | 0950-9232 | - |
dc.identifier.uri | https://hdl.handle.net/10371/184867 | - |
dc.description.abstract | Despite recent advances, there remains a significant unmet need for the development of new targeted therapies for triple-negative breast cancer (TNBC). Although the heat shock protein HSP90 is a promising target, previous inhibitors have had issues during development including undesirable induction of the heat shock response (HSR) and off-target effects leading to toxicity. SL-145 is a novel, rationally-designed C-terminal HSP90 inhibitor that induces apoptosis in TNBC cells via the suppression of oncogenic AKT, MEK/ERK, and JAK2/STAT3 signaling and does not trigger the HSR, in contrast to other inhibitors. In an orthotopic allograft model incorporating breast cancer stem cell-enriched TNBC tumors, SL-145 potently suppressed tumor growth, angiogenesis, and metastases concomitant with dysregulation of the JAK2/STAT3 signaling pathway. Our findings highlight the potential of SL-145 in suppressing metastatic TNBC independent of the HSR. | - |
dc.language | 영어 | - |
dc.publisher | Nature Publishing Group | - |
dc.title | A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response | - |
dc.type | Article | - |
dc.identifier.doi | 10.1038/s41388-022-02269-y | - |
dc.citation.journaltitle | Oncogene | - |
dc.identifier.wosid | 000789736500002 | - |
dc.identifier.scopusid | 2-s2.0-85129323112 | - |
dc.citation.endpage | 3297 | - |
dc.citation.number | 23 | - |
dc.citation.startpage | 3289 | - |
dc.citation.volume | 41 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Lee, Jeewoo | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.